Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Flutamide

Flutamide: A Complete Guide to the Anti-Androgen in Prostate Cancer Therapy

Introduction

Hormonal therapy has long played a pivotal role in the management of prostate cancer and other androgen-sensitive conditions. Among the key players in this domain is Flutamide, a non-steroidal anti-androgen known for its ability to block the action of testosterone at the cellular level. Developed in the 1960s and approved for medical use in the 1980s, flutamide has since become a cornerstone in prostate cancer treatment, particularly in combination with luteinizing hormone-releasing hormone (LHRH) agonists. Though newer agents have entered the market, flutamide remains relevant due to its cost-effectiveness and established clinical efficacy.

1. Flutamide

Flutamide is a non-steroidal anti-androgen (NSAA) that works by blocking androgen receptors, preventing the action of testosterone and dihydrotestosterone (DHT) in target tissues.

  • Chemical Name: 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide

  • Drug Class: Non-steroidal anti-androgen

  • Formulation: Oral tablets

  • Brand Names: Eulexin, Drogenil (and generics)

  • FDA Approval: 1989 (for prostate cancer)

Flutamide is not a hormone but mimics the structure of androgens enough to bind to their receptors—without activating them.

2. Mechanism of Action

Flutamide exerts its effect by:

  • Competing with testosterone and DHT for androgen receptors in prostate cells

  • Blocking androgen-driven cellular proliferation in prostate tissues

  • Preventing androgen binding to the receptor without initiating gene transcription

In men with prostate cancer, where tumor growth is driven by androgens, flutamide’s receptor blockade effectively slows or halts tumor progression.

3. Clinical Indications

✅ Prostate Cancer

Flutamide is primarily indicated for:

  • Advanced prostate cancer

  • Metastatic disease

  • In combination with LHRH agonists (e.g., leuprolide or goserelin)

This combined approach is known as Complete Androgen Blockade (CAB), which reduces androgen levels while also blocking receptor activity.

✅ Off-label Uses

Though not FDA-approved, flutamide has been used in women and transgender individuals for androgen-related disorders:

  • Polycystic Ovary Syndrome (PCOS): For hirsutism and acne

  • Female androgenic alopecia

  • Transgender hormone therapy: As part of feminizing hormone regimens

Caution is advised in these populations due to hepatic risks.

4. Pharmacokinetics

  • Absorption: Rapid oral absorption

  • Bioavailability: >90%

  • Metabolism: Hepatic (CYP1A2), to active metabolite 2-hydroxyflutamide

  • Half-life: Parent compound – 6 hours; Active metabolite – 8 hours

  • Excretion: Primarily urine

Due to its short half-life, flutamide is typically administered three times daily, unlike newer agents with once-daily dosing.

5. Dosage and Administration

Standard Dosage:

  • 250 mg orally three times daily (every 8 hours)

In CAB (combined with LHRH agonist):

  • Flutamide is started several days before the LHRH agonist to prevent tumor flare.

Important Considerations:

  • Monitor liver function tests before and during therapy

  • Take with food to reduce gastrointestinal irritation

6. Advantages of Flutamide

Despite newer alternatives, flutamide offers several benefits:

Cost-Effective

  • Widely available in generic forms

  • Affordable option, especially in low-resource settings

Proven Efficacy

  • Decades of clinical use with substantial data supporting its effectiveness

Useful in CAB

  • Effective when used in combination for complete androgen blockade

Oral Administration

  • Non-invasive and easy to manage for patients at home

7. Side Effects and Risks

Like most hormonal therapies, flutamide is associated with a range of adverse effects, some of which can be serious.

Common Side Effects

  • Gynecomastia

  • Hot flashes

  • Loss of libido

  • Impotence

  • Gastrointestinal upset (nausea, diarrhea)

  • Weight gain

Serious Risks

Hepatotoxicity

  • The most significant risk associated with flutamide

  • Can lead to fatal liver failure

  • Monitor ALT, AST, bilirubin regularly

  • Watch for symptoms: jaundice, fatigue, dark urine, abdominal pain

Anemia

  • Rare but possible; requires CBC monitoring

Interstitial Pneumonitis

  • Very rare, but potentially life-threatening

8. Contraindications

Flutamide should not be used in:

  • Patients with severe liver disease

  • Those with a history of flutamide-induced liver toxicity

  • Women who are pregnant or breastfeeding

  • Individuals allergic to flutamide or any component of the formulation

Caution is advised when combining with other hepatotoxic medications.

9. Drug Interactions

Flutamide is metabolized by the CYP1A2 enzyme, so caution is needed when used with:

  • Theophylline: Increased serum levels

  • Warfarin: Potential for increased bleeding risk

  • Cimetidine: May increase flutamide levels

Always conduct a thorough medication review before starting flutamide.

10. Comparison With Other Anti-Androgens

Feature Flutamide Bicalutamide Enzalutamide Apalutamide
Dosing 250 mg TID 50–150 mg QD 160 mg QD 240 mg QD
Liver Risk High Moderate Low Low
CNS Effects Minimal Minimal Seizure risk Seizure risk
Cost Low Moderate High High
Use in CAB Yes Yes No (monotherapy) No (monotherapy)

Though newer agents offer improved pharmacokinetics and reduced toxicity, flutamide remains a viable option in certain clinical scenarios.

11. Flutamide in Women and Transgender Medicine

While off-label, flutamide has been used for hormonal conditions in women, such as:

PCOS and Hirsutism

  • Effective in reducing androgenic symptoms

  • Alternative to spironolactone when potassium-sparing effects are undesirable

Female Pattern Hair Loss

  • Slows progression in androgen-driven alopecia

Transfeminine Therapy

  • Sometimes used to block testosterone when spironolactone or cyproterone is not tolerated

Important Note: Hepatic monitoring is critical in all these uses, and risks must be carefully weighed.

12. Monitoring and Follow-Up

Patients on flutamide require regular follow-up, especially during the first few months:

  • Liver function tests: Baseline, then monthly for the first 4 months, then periodically

  • Prostate-Specific Antigen (PSA) levels: To monitor treatment response

  • CBC: If anemia or fatigue is suspected

  • Sexual function and quality of life: Especially in long-term treatment

Patient education is essential for recognizing early signs of liver dysfunction.

13. Historical Perspective

Flutamide was one of the first oral anti-androgens introduced for prostate cancer. It marked a shift from orchiectomy and estrogen therapy toward more targeted hormonal manipulation.

Its development laid the groundwork for more potent and selective agents like bicalutamide, enzalutamide, and apalutamide.

Despite being somewhat overshadowed today, it remains in use, especially where cost is a limiting factor or in combination regimens.

14. Legal and Regulatory Status

  • FDA-approved in the U.S. for metastatic prostate cancer

  • Withdrawn in some countries due to hepatotoxicity concerns

  • Still available globally, especially in Asia, South America, and Eastern Europe

Medical professionals are advised to consult local prescribing guidelines.

15. Future Outlook

Though flutamide use is declining in many developed countries, it continues to offer value in global oncology care, particularly:

  • As a bridge therapy

  • For resource-limited settings

  • In hormone-sensitive stages of prostate cancer

Researchers are also exploring topical flutamide formulations to reduce systemic exposure and minimize liver risk.

Conclusion

Flutamide, a pioneering non-steroidal anti-androgen, holds a unique place in the management of androgen-driven conditions, particularly prostate cancer. With its affordable cost, oral dosing, and well-understood mechanism, it remains a useful agent—though newer drugs have taken center stage due to superior safety profiles and convenience. When prescribed appropriately and monitored closely, flutamide continues to serve as a valuable part of the urologist's and oncologist's toolkit, especially in complete androgen blockade and low-resource environments.